Stoke Therapeutics, Inc. STOK MECP2 — Operating Expenses

Other product segments

Similar metrics at other companies

SLSTotal costs & expenses

$9.25M+52.6%

BHVNTotal costs & expenses

$130.43M-41.1%

AGIOTotal costs & expenses

$130.77M+13.4%

CRNXTotal costs & expenses

$151.11M+35.2%

BCRXBCX17725 — Research and Development Expense (Excluding Acquired in Process Cost)

$1.91M-22.4%

HHHMPC Segment — Operating costs

$13.14M+1.1%

Questions, answered.

What is Stoke Therapeutics, Inc.'s MECP2 — operating expenses?

Stoke Therapeutics, Inc. (STOK) reported MECP2 — operating expenses of $0 in Q1 2026.

How has Stoke Therapeutics, Inc.'s MECP2 — operating expenses changed year-over-year?

Stoke Therapeutics, Inc.'s MECP2 — operating expenses increased by 100.0% year-over-year, from -$147K to $0.

What is the long-term trend for Stoke Therapeutics, Inc.'s MECP2 — operating expenses?

Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s MECP2 — operating expenses has grown at a -80.7% compound annual growth rate (CAGR), from -$991K to $37K.

What does MECP2 — operating expenses mean?

This metric represents the total costs directly attributable to the research, development, and operational activities associated with the MECP2 therapeutic program. It captures the investment required to advance this specific pipeline asset through preclinical and clinical stages, including personnel, laboratory, and external trial costs. Monitoring these expenses provides insight into the capital intensity and resource allocation strategy for this specific drug development candidate.